Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2012 2
2013 3
2014 1
2015 2
2017 3
2019 1
2020 1
2021 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.
Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, Delgado RF, Alexander S, Uyttebroeck A, Bollard CM, Zsiros J, Csoka M, Kazanowska B, Chiang AK, Miles RR, Wotherspoon A, Adamson PC, Vassal G, Patte C, Gross TG; European Intergroup for Childhood Non-Hodgkin Lymphoma; Children’s Oncology Group. Minard-Colin V, et al. N Engl J Med. 2020 Jun 4;382(23):2207-2219. doi: 10.1056/NEJMoa1915315. N Engl J Med. 2020. PMID: 32492302 Free PMC article. Clinical Trial.
Thalassemias.
Martin A, Thompson AA. Martin A, et al. Pediatr Clin North Am. 2013 Dec;60(6):1383-91. doi: 10.1016/j.pcl.2013.08.008. Epub 2013 Oct 4. Pediatr Clin North Am. 2013. PMID: 24237977 Review.
Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells.
Yankelevich M, Thakur A, Modak S, Chu R, Taub J, Martin A, Schalk DL, Schienshang A, Whitaker S, Rea K, Lee DW, Liu Q, Shields A, Cheung NK, Lum LG. Yankelevich M, et al. Among authors: martin a. Res Sq [Preprint]. 2023 Nov 9:rs.3.rs-3570311. doi: 10.21203/rs.3.rs-3570311/v1. Res Sq. 2023. PMID: 37986911 Free PMC article. Updated. Preprint.
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.
Yankelevich M, Thakur A, Modak S, Chu R, Taub J, Martin A, Schalk D, Schienshang A, Whitaker S, Rea K, Lee DW, Liu Q, Shields AF, Cheung NV, Lum LG. Yankelevich M, et al. Among authors: martin a. J Immunother Cancer. 2024 Mar 21;12(3):e008744. doi: 10.1136/jitc-2023-008744. J Immunother Cancer. 2024. PMID: 38519053 Free PMC article. Clinical Trial.
Differentially expressed miRNAs in retinoblastoma.
Martin J, Bryar P, Mets M, Weinstein J, Jones A, Martin A, Vanin EF, Scholtens D, Costa FF, Soares MB, Laurie NA. Martin J, et al. Among authors: martin a. Gene. 2013 Jan 10;512(2):294-9. doi: 10.1016/j.gene.2012.09.129. Epub 2012 Oct 26. Gene. 2013. PMID: 23103829 Clinical Trial.
17 results